83 Results

People

  1. Hammerling
    Hammerling
  2. Schantz
    Schantz
  3. Dmitrovsky
    Dmitrovsky
  4. Halpern
    Halpern
  5. Levi
    Levi
  6. Sacks
    Sacks
  7. Scher
    Scher
  8. Warrell
    Warrell
  9. Buck
    Buck
  10. Busam
    Busam

Groups

  1. Department of Medicine (30)
  2. Division of Subspecialty Medicine (18)
  3. Dermatology Service (15)
  4. Dermatology (15)
  5. Solid Tumor Oncology Division (11)
  6. Survivorship Research (11)
  7. Population Sciences Research Program (9)
  8. Surgery (7)
  9. Center for Hematologic Malignancies (6)
  10. Genitourinary Oncology Service (6)
  1. "retinoid"
Formats
  1. Journal Article (77)
  2. Conference Paper (4)
  3. Review (2)
Groups
  1. Department of Medicine (30)
  2. Division of Subspecialty Medicine (18)
  3. Dermatology (15)
  4. Dermatology Service (15)
  5. Solid Tumor Oncology Division (11)
  6. Survivorship Research (11)

More Groups

People
  1. Ulrich Hammerling (7)
  2. Stimson Schantz (6)
  3. Allan Halpern (4)
  4. Ester Levi (4)
  5. Ethan Dmitrovsky (4)
  6. Howard Scher (4)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2021 (1)
  4. 2019 (2)
  5. 2017 (1)
  6. 2016 (1)

More Years

Publications
  1. Cancer Research (5)
  2. Current Opinion in Oncology (3)
  3. International Journal of Cancer (3)
  4. Cancer (2)
  5. Clinical Advances in Hematology & Oncology (2)
  6. JNCI: Journal of the National Cancer Institute (2)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. American Association for Cancer Research (6)
  3. John Wiley & Sons (5)
  4. Lippincott Williams & Wilkins (5)
  5. Springer (5)
  6. Nature Publishing Group (4)

More Publishers

Results (83)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
    Journal Article

    Plumber, S. A.; Tate, T.; Al-Ahmadie, H.; Chen, X.; Choi, W.; Basar, M.; Lu, C.; Viny, A.; Batourina, E.; Li, J.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Use of tamibarotene, a potent and selective RARĪ± agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
    Journal Article

    Stein, E. M.; de Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Roboz, G. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Practice patterns regarding combination treatments and laser and energy based devices: A survey of American Society for Laser Medicine and Surgery Members
    Journal Article

    Dempsey, A.; Watchmaker, J.; Hibler, B. P.; Rossi, A.
    Lasers in Surgery and Medicine (2023)

    Fulltext@MSK | Save
  • Immune-related cutaneous adverse events due to checkpoint inhibitors
    Review

    Wang, E.; Kraehenbuehl, L.; Ketosugbo, K.; Kern, J. A.; Lacouture, M. E.; Leung, D. Y. M.
    Annals of Allergy, Asthma & Immunology (2021)

    Fulltext@MSK | Save
  • Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies
    Review

    Bens, A.; Langballe, R.; Bernstein, J. L.; Cronin-Fenton, D.; Friis, S.; Mellemkjaer, L.
    Acta Oncologica (2019)

    Fulltext@MSK | Save
  • A new target in CTCL: Treating the skin, blood, and lymph nodes [interview]
    Journal Article

    Horwitz, S. M.
    Clinical Advances in Hematology & Oncology (2019)

    Fulltext@MSK | Save
  • Ponatinib-induced ichthyosiform drug eruption: Insights into acquired ichthyosis
    Journal Article

    Xu, H.; Busam, K. J.; Mauro, M. J.; Markova, A.
    Dermatology Online Journal (2017)

    Fulltext@MSK | Save
  • Cancer-treatment-induced neurotoxicity - Focus on newer treatments
    Journal Article

    Stone, J. B.; DeAngelis, L. M.
    Nature Reviews Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Emerging treatments and aignaling pathway inhibitors
    Journal Article

    Tang, J. Y.; Marghoob, A. A.
    Seminars in Cutaneous Medicine and Surgery (2011)

    Fulltext@MSK | Save
  • Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): An intergroup trial coordinated by the Eastern Cooperative Oncology Group
    Journal Article

    Rao, R. D.; Cobleigh, M. A.; Gray, R.; Graham, M. L. 2nd; Norton, L.; Martino, S.; Budd, G. T.; Ingle, J. N.; Wood, W. C.
    Medical Oncology (2011)

    Fulltext@MSK | Save